Abraxane and Hepatic function abnormal - a phase IV clinical study of FDA data

Summary:

Hepatic function abnormal is reported as a side effect among people who take Abraxane (paclitaxel), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Keytruda, and have Lung cancer - non-small cell.

The phase IV clinical study analyzes which people have Hepatic function abnormal when taking Abraxane. It is created by eHealthMe based on reports of 19,123 people who have side effects when taking Abraxane from the FDA, and is updated regularly.

What is Abraxane?

Abraxane has active ingredients of paclitaxel. It is often used in breast cancer metastatic. eHealthMe is studying from 19,196 Abraxane users. Check the latest studies of Abraxane.

What is Hepatic function abnormal?

Hepatic function abnormal is found to be associated with 1,487 drugs and 2,010 conditions by eHealthMe. Check the latest studies of Hepatic function abnormal.

On Nov, 06, 2025

19,123 people reported to have side effects when taking Abraxane.
Among them, 150 people (0.78%) have Hepatic function abnormal.

Could Abraxane cause Hepatic function abnormal?

Among these 150 people:

How long have people been on Abraxane when they have Hepatic function abnormal? *

What is the gender of people who have Hepatic function abnormal when taking Abraxane? *

female: 59.56 %
male: 40.44 %

What is the age of people who have Hepatic function abnormal when taking Abraxane? *

What are other drugs people take besides Abraxane? *

What are other side effects people have besides Hepatic function abnormal? *

Thrombocytopenia (decrease of platelets in blood): 16 people, 10.67%
Nausea (feeling of having an urge to vomit): 15 people, 10.00%
Anaemia (lack of blood): 15 people, 10.00%
Hair Loss: 14 people, 9.33%
Leukopenia (less number of white blood cells in blood): 13 people, 8.67%
Neutrophil Count Decreased (less than normal number of neutrophil a type of blood cell): 12 people, 8.00%
Diarrhea: 12 people, 8.00%
Alanine Aminotransferase Increased: 11 people, 7.33%
Nausea And Vomiting: 11 people, 7.33%
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 11 people, 7.33%

What are the existing conditions these people have? *

Lung Cancer - Non-Small Cell (lung cancer): 26 people, 17.33%
Constipation: 20 people, 13.33%
Insomnia (sleeplessness): 12 people, 8.00%
Pancreatic Carcinoma Metastatic (pancreatic cancer- metastatic): 11 people, 7.33%
Nausea (feeling of having an urge to vomit): 11 people, 7.33%
Gastritis (inflammation of stomach): 9 people, 6.00%
Non-Small Cell Lung Cancer Stage Iv: 8 people, 5.33%
Lung Neoplasm Malignant (cancer tumour of lung): 8 people, 5.33%
High Blood Cholesterol: 8 people, 5.33%
Depression: 8 people, 5.33%

* Approximation only. Some reports may have incomplete information.

Do you take Abraxane and have Hepatic function abnormal?

- Check whether Hepatic function abnormal is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Abraxane:

Abraxane (19,196 reports)

Common Abraxane side effects:

Browse all side effects of Abraxane:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common drugs associated with Hepatic function abnormal:

Browse all the drugs that are associated with Hepatic function abnormal:

Hepatic function abnormal (1,487 drugs)

Common conditions associated with Hepatic function abnormal:

Hypertension: 2,738 reports
Rheumatoid arthritis: 1,426 reports
Cancer - kidney: 1,400 reports
Preventive health care: 1,380 reports
Non-small cell lung cancer: 1,251 reports
Breast cancer: 1,019 reports
Constipation: 971 reports
Sleeping: 966 reports
Hyperlipidaemia: 949 reports
Dm: 940 reports

Browse all the conditions that are associated with Hepatic function abnormal:

Hepatic function abnormal (2,010 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on paclitaxel (the active ingredients of Abraxane) and Abraxane (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.